Schering's Say-on-Pay Survey Goes M.I.A.
Did Schering-Plough plan -- and then kill or delay -- a "say on pay" survey of its investors? That's one possibility raised by "Condor" at Shearlings Got Plowed, the blog that obsessively examines goings-on at the company that's soon to be merged into Merck.
A say-on-pay survey of Schering investors would be most interesting because CEO Fred Hassan's compensation is famously lavish. BNET previously estimated his payout in the Merck merger at $77 million. Condor thinks it could be $173 million. The WSJ estimates a "mere" $56 million.
Condor's post relies on this blog item by a lawyer named Raphael M. Russo at Paul, Weiss, Rifkind, Wharton & Garrison. The item states:
... the company is evaluating a process to complete and discuss the survey before the proposed transaction with Merck closes.No survey was included with the Schering proxy filing, Condor reports. Which raises the question: If the survey was planned but didn't go out to investors with the proxy materials, when, if ever, does Schering want to see that vote published?
Adding to the mystery: blogger/lawyer Russo and Schering board member Patricia F. Russo, former CEO of Alcatel-Lucent, share the same last name. Does one Russo know something the rest of us don't?
- Related:
- Inside Schering's $437M Tax Fraud: "It Doesn't Count If It's in Dutch!"
- Schering's Weird New Nuvaring Ad: "Don't You Have to -- Put It In --?"
- Zyrtec and Claritin's New Eye Drops Contain Neither Zyrtec Nor Claritin
- Leerink Outlines Gloom Potential for Merck/Schering's $2B Zetia Franchise
- Judge Details Schering's "Reprehensible" Off-Label Promotion of Cancer Drugs
- Merck and Schering Q2: Who Needs This Merger More?
- Schering CEO Hassan's Merck Payout Is Millions Greater Than WSJ Thinks It Is
- Does J&J's Move on Remicade Pact Threaten Schering CEO Hassan's $51 Mil. Merger Payout?
- Top Schering Execs Could Get $132 Million in Merck Deal Jackpot
- Schering CEO Hassan Has $59 Million Buyout Agreement in Merck Merger